{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:04:48Z","timestamp":1795089888957,"version":"4.10.2"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41584-024-01135-3","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:19:59Z","timestamp":1720523999000},"page":"473-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":238,"title":["Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-1824","authenticated-orcid":false,"given":"Chiara","family":"Baldini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-4412","authenticated-orcid":false,"given":"Giovanni","family":"Fulvio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-7090","authenticated-orcid":false,"given":"Gaetano","family":"La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"1135_CR1","first-page":"97","volume":"379","author":"X Mariette","year":"2018","unstructured":"Mariette, X. & Criswell, L. A. Primary Sj\u00f6gren\u2019s Syndrome. N. Engl. J. Med. 379, 97 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1135_CR2","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n, P. et al. Sj\u00f6gren syndrome. Nat. Rev. Dis. Prim. 2, 16047 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/acr.21956","volume":"65","author":"BM Segal","year":"2013","unstructured":"Segal, B. M., Pogatchnik, B., Henn, L., Rudser, K. & Sivils, K. M. Pain severity and neuropathic pain symptoms in primary Sj\u00f6gren\u2019s syndrome: a comparison study of seropositive and seronegative Sj\u00f6gren\u2019s syndrome patients. Arthritis Care Res. 65, 1291\u20131298 (2013).","journal-title":"Arthritis Care Res."},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"703079","DOI":"10.3389\/fimmu.2021.703079","volume":"12","author":"E M\u00e6land","year":"2021","unstructured":"M\u00e6land, E., Miyamoto, S. T., Hammenfors, D., Valim, V. & Jonsson, M. V. Understanding fatigue in Sj\u00f6gren\u2019s syndrome: outcome measures, biomarkers and possible interventions. Front. Immunol. 12, 703079 (2021).","journal-title":"Front. Immunol."},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"770422","DOI":"10.3389\/fmed.2021.770422","volume":"8","author":"J Unger","year":"2021","unstructured":"Unger, J. et al. The experiences of functioning and health of patients with primary Sj\u00f6gren\u2019s syndrome: a multicenter qualitative European study. Front. Med. 8, 770422 (2021).","journal-title":"Front. Med."},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","volume":"20","author":"M Beydon","year":"2024","unstructured":"Beydon, M. et al. Epidemiology of Sjogren syndrome. Nat. Rev. Rheumatol. 20, 158\u2013169 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3899\/jrheum.200733","volume":"48","author":"SS McCoy","year":"2021","unstructured":"McCoy, S. S. et al. National Sj\u00f6gren\u2019s foundation survey: burden of oral and systemic involvement on quality of life. J. Rheumatol. 48, 1029\u20131036 (2021).","journal-title":"J. Rheumatol."},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/joim.13451","volume":"291","author":"J Tarn","year":"2022","unstructured":"Tarn, J. et al. Primary Sj\u00f6gren\u2019s syndrome: longitudinal real-world, observational data on health-related quality of life. J. Intern. Med. 291, 849\u2013855 (2022).","journal-title":"J. Intern. Med."},{"key":"1135_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/art.41676","volume":"73","author":"AN Baer","year":"2021","unstructured":"Baer, A. N. & Hammitt, K. M. Sjogren\u2019s disease, not syndrome. Arthritis Rheumatol. 73, 1347\u20131348 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR10","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.55563\/clinexprheumatol\/3y0hqs","volume":"40","author":"C Baldini","year":"2022","unstructured":"Baldini, C., Bartoloni, E. & Bombardieri, M. Highlights of the 15th International Symposium on Sjogren\u2019s Syndrome. Clin. Exp. Rheumatol. 40, 2201\u20132210 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001064","volume":"5","author":"P Brito-Zer\u00f3n","year":"2019","unstructured":"Brito-Zer\u00f3n, P. et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome. RMD Open. 5, e001064 (2019).","journal-title":"RMD Open."},{"key":"1135_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2019.04.009","volume":"203","author":"FB Vivino","year":"2019","unstructured":"Vivino, F. B. et al. Sjogren\u2019s syndrome: an update on disease pathogenesis, clinical manifestations and treatment. Clin. Immunol. 203, 81\u2013121 (2019).","journal-title":"Clin. Immunol."},{"key":"1135_CR13","first-page":"315","volume":"38","author":"S Fasano","year":"2020","unstructured":"Fasano, S. et al. Pathogenesis of primary Sj\u00f6gren\u2019s syndrome beyond B lymphocytes. Clin. Exp. Rheumatol. 38, 315\u2013323 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","volume":"60","author":"RI Fox","year":"2021","unstructured":"Fox, R. I., Fox, C. M., Gottenberg, J. E. & D\u00f6rner, T. Treatment of Sj\u00f6gren\u2019s syndrome: current therapy and future directions. Rheumatology 60, 2066\u20132074 (2021).","journal-title":"Rheumatology"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1080\/14656566.2021.1951224","volume":"22","author":"S Retamozo","year":"2021","unstructured":"Retamozo, S., Sis\u00f3-Almirall, A., Flores-Ch\u00e1vez, A., Ramos-Casals, M. & Brito-Zer\u00f3n, P. An update of targeted therapeutic options for primary Sj\u00f6gren syndrome: current status and future development. Expert. Opin. Pharmacother. 22, 2359\u20132371 (2021).","journal-title":"Expert. Opin. Pharmacother."},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/14728222.2022.2157259","volume":"26","author":"D Ridgewell","year":"2022","unstructured":"Ridgewell, D., Thalayasingam, N. & Ng, W. F. Sj\u00f6gren\u2019s syndrome: shedding light on emerging and key drug targets. Expert. Opin. Ther. Targets 26, 869\u2013882 (2022).","journal-title":"Expert. Opin. Ther. Targets"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"1127417","DOI":"10.3389\/fimmu.2023.1127417","volume":"14","author":"Q Zhan","year":"2023","unstructured":"Zhan, Q. et al. Pathogenesis and treatment of Sjogren\u2019s syndrome: review and update. Front. Immunol. 14, 1127417 (2023).","journal-title":"Front. Immunol."},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728214.2023.2209720","volume":"28","author":"RI Fox","year":"2023","unstructured":"Fox, R. I., Fox, C. M. & McCoy, S. S. Emerging treatment for Sj\u00f6gren\u2019s disease: a review of recent phase II and III trials. Expert. Opin. Emerg. Drugs 28, 107\u2013120 (2023).","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"1135_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/art.42789","volume":"76","author":"E Bettacchioli","year":"2023","unstructured":"Bettacchioli, E. et al. Association of combined anti-Ro52\/TRIM21 and anti-Ro60\/SSA antibodies with increased Sj\u00f6gren disease severity through interferon pathway activation. Arthritis Rheumatol. 76, 751\u2013762 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/rheumatology\/kez335","volume":"59","author":"JA James","year":"2020","unstructured":"James, J. A. et al. Unique Sj\u00f6gren\u2019s syndrome patient subsets defined by molecular features. Rheumatology 59, 860\u2013868 (2020).","journal-title":"Rheumatology"},{"key":"1135_CR21","first-page":"198","volume":"36","author":"P Brito-Zer\u00f3n","year":"2018","unstructured":"Brito-Zer\u00f3n, P., Retamozo, S. & Ramos-Casals, M. Phenotyping Sj\u00f6gren\u2019s syndrome: towards a personalised management of the disease. Clin. Exp. Rheumatol. 36, 198\u2013209 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR22","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","volume":"1","author":"JR Tarn","year":"2019","unstructured":"Tarn, J. R. et al. Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 1, e85\u2013e94 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1135_CR23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/art.42238","volume":"74","author":"SS McCoy","year":"2022","unstructured":"McCoy, S. S. et al. Symptom-based cluster analysis categorizes Sj\u00f6gren\u2019s disease subtypes: an international cohort study highlighting disease severity and treatment discordance. Arthritis Rheumatol. 74, 1569\u20131579 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR24","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.berh.2019.101475","volume":"34","author":"G Noaiseh","year":"2020","unstructured":"Noaiseh, G. & Baer, A. N. Toward better outcomes in Sj\u00f6gren\u2019s syndrome: the promise of a stratified medicine approach. Best. Pract. Res. Clin. Rheumatol. 34, 101475 (2020).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1135_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.revmed.2023.07.001","volume":"44","author":"V Devauchelle-Pensec","year":"2023","unstructured":"Devauchelle-Pensec, V. et al. French national diagnostic and care protocol for Sjogren\u2019s disease. Rev. Med. Interne 44, 423\u2013457 (2023).","journal-title":"Rev. Med. Interne"},{"key":"1135_CR26","first-page":"283","volume":"38","author":"L de Wolff","year":"2020","unstructured":"de Wolff, L., Arends, S., van Nimwegen, J. F. & Bootsma, H. Ten years of the ESSDAI: is it fit for purpose? Clin. Exp. Rheumatol. 38, 283\u2013290 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror, R. et al. Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 81, 979\u2013989 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/annrheumdis-2016-209952","volume":"76","author":"P Brito-Zer\u00f3n","year":"2017","unstructured":"Brito-Zer\u00f3n, P. et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sj\u00f6gren\u2019s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sj\u00f6gren Project Consortium. Ann. Rheum. Dis. 76, 1042\u20131050 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","volume":"9","author":"G Nocturne","year":"2013","unstructured":"Nocturne, G. & Mariette, X. Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Nat. Rev. Rheumatol. 9, 544\u2013556 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","volume":"19","author":"GE Thorlacius","year":"2023","unstructured":"Thorlacius, G. E., Bj\u00f6rk, A. & Wahren-Herlenius, M. Genetics and epigenetics of primary Sj\u00f6gren syndrome: implications for future therapies. Nat. Rev. Rheumatol. 19, 288\u2013306 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","volume":"17","author":"GM Verstappen","year":"2021","unstructured":"Verstappen, G. M., Pringle, S., Bootsma, H. & Kroese, F. G. M. Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 17, 333\u2013348 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/1744666X.2021.1879641","volume":"17","author":"L Chatzis","year":"2021","unstructured":"Chatzis, L., Vlachoyiannopoulos, P. G., Tzioufas, A. G. & Goules, A. V. New frontiers in precision medicine for Sjogren\u2019s syndrome. Expert. Rev. Clin. Immunol. 17, 127\u2013141 (2021).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1135_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/joim.13032","volume":"287","author":"A Bj\u00f6rk","year":"2020","unstructured":"Bj\u00f6rk, A., Mofors, J. & Wahren-Herlenius, M. Environmental factors in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. J. Intern. Med. 287, 475\u2013492 (2020).","journal-title":"J. Intern. Med."},{"key":"1135_CR34","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/ng.2792","volume":"45","author":"CJ Lessard","year":"2013","unstructured":"Lessard, C. J. et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj\u00f6gren\u2019s syndrome. Nat. Genet. 45, 1284\u20131292 (2013).","journal-title":"Nat. Genet."},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1002\/art.38123","volume":"65","author":"H Yin","year":"2013","unstructured":"Yin, H. et al. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sj\u00f6gren\u2019s syndrome and in mice. Arthritis Rheum. 65, 3228\u20133238 (2013).","journal-title":"Arthritis Rheum."},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/annrheumdis-2020-219649","volume":"80","author":"H Nakamura","year":"2021","unstructured":"Nakamura, H. et al. Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sj\u00f6gren\u2019s syndrome-like phenotype in mice. Ann. Rheum. Dis. 80, 1031\u20131039 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152780","volume":"132","author":"YQ Mo","year":"2022","unstructured":"Mo, Y. Q. et al. Lysosomal exocytosis of HSP70 stimulates monocytic BMP6 expression in Sj\u00f6gren\u2019s syndrome. J. Clin. Invest. 132, e152780 (2022).","journal-title":"J. Clin. Invest."},{"key":"1135_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/jleuko\/qiad049","volume":"115","author":"Y Tang","year":"2023","unstructured":"Tang, Y. et al. The role of epithelial cells in the immunopathogenesis of Sj\u00f6gren\u2019s syndrome. J. Leukoc. Biol. 115, 57\u201367 (2023).","journal-title":"J. Leukoc. Biol."},{"key":"1135_CR39","doi-asserted-by":"publisher","first-page":"11179","DOI":"10.3390\/ijms241311179","volume":"24","author":"Y Yura","year":"2023","unstructured":"Yura, Y. & Hamada, M. Outline of salivary gland pathogenesis of Sj\u00f6gren\u2019s syndrome and current therapeutic approaches. Int. J. Mol. Sci. 24, 11179 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR40","doi-asserted-by":"publisher","first-page":"676010","DOI":"10.3389\/fimmu.2021.676010","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. TLR7 signaling drives the development of Sj\u00f6gren\u2019s syndrome. Front. Immunol. 12, 676010 (2021).","journal-title":"Front. Immunol."},{"key":"1135_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","volume":"63","author":"A Nezos","year":"2015","unstructured":"Nezos, A. et al. Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis. J. Autoimmun. 63, 47\u201358 (2015).","journal-title":"J. Autoimmun."},{"key":"1135_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal. Transduct. Target. Ther. 6, 402 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1135_CR43","first-page":"185","volume":"37","author":"N Marketos","year":"2019","unstructured":"Marketos, N., Cinoku, I., Rapti, A. & Mavragani, C. P. Type I interferon signature in Sj\u00f6gren\u2019s syndrome: pathophysiological and clinical implications. Clin. Exp. Rheumatol. 37, 185\u2013191 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/biom11020251","volume":"11","author":"N Del Papa","year":"2021","unstructured":"Del Papa, N. et al. The role of interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome and future therapeutic perspectives. Biomolecules 11, 251 (2021).","journal-title":"Biomolecules"},{"key":"1135_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","volume":"68","author":"CP Mavragani","year":"2017","unstructured":"Mavragani, C. P. Mechanisms and new strategies for primary Sj\u00f6gren\u2019s syndrome. Annu. Rev. Med. 68, 331\u2013343 (2017).","journal-title":"Annu. Rev. Med."},{"key":"1135_CR46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/ijms21020650","volume":"21","author":"CS de Paiva","year":"2020","unstructured":"de Paiva, C. S. & Pflugfelder, S. C. Mechanisms of disease in Sj\u00f6gren syndrome \u2014 new developments and directions. Int. J. Mol. Sci. 21, 650 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR47","doi-asserted-by":"publisher","first-page":"12765","DOI":"10.3390\/ijms232112765","volume":"23","author":"JM Sequi-Sabater","year":"2022","unstructured":"Sequi-Sabater, J. M. & Beretta, L. Defining the role of monocytes in Sj\u00f6gren\u2019s syndrome. Int. J. Mol. Sci. 23, 12765 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR48","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","volume":"60","author":"ILA Bodewes","year":"2019","unstructured":"Bodewes, I. L. A., Bj\u00f6rk, A., Versnel, M. A. & Wahren-Herlenius, M. Innate immunity and interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome. Rheumatology 60, 2561\u20132573 (2019).","journal-title":"Rheumatology"},{"key":"1135_CR49","first-page":"1131","volume":"20","author":"J Qi","year":"2019","unstructured":"Qi, J. et al. Interleukin-12 exacerbates Sj\u00f6gren\u2019s syndrome through induction of myeloid-derived suppressor cells. Mol. Med. Rep. 20, 1131\u20131138 (2019).","journal-title":"Mol. Med. Rep."},{"key":"1135_CR50","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/ard.2009.115378","volume":"69","author":"N Roescher","year":"2010","unstructured":"Roescher, N., Tak, P. P. & Illei, G. G. Cytokines in Sj\u00f6gren\u2019s syndrome: potential therapeutic targets. Ann. Rheum. Dis. 69, 945\u2013948 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR51","doi-asserted-by":"publisher","first-page":"884399","DOI":"10.3389\/fimmu.2022.884399","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Novel small molecule tyrosine kinase 2 pseudokinase ligands block cytokine-induced TYK2-mediated signaling pathways. Front. Immunol. 13, 884399 (2022).","journal-title":"Front. Immunol."},{"key":"1135_CR52","first-page":"1563","volume":"19","author":"KA Ullrich","year":"2020","unstructured":"Ullrich, K. A. et al. Immunology of IL-12: an update on functional activities and implications for disease. EXCLI J. 19, 1563\u20131589 (2020).","journal-title":"EXCLI J."},{"key":"1135_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne, G. & Mariette, X. B cells in the pathogenesis of primary Sj\u00f6gren syndrome. Nat. Rev. Rheumatol. 14, 133\u2013145 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1135_CR54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/bmm-2017-0297","volume":"12","author":"C Baldini","year":"2018","unstructured":"Baldini, C., Ferro, F., Elefante, E. & Bombardieri, S. Biomarkers for Sj\u00f6gren\u2019s syndrome. Biomark. Med. 12, 275\u2013286 (2018).","journal-title":"Biomark. Med."},{"key":"1135_CR55","doi-asserted-by":"publisher","first-page":"103425","DOI":"10.1016\/j.autrev.2023.103425","volume":"23","author":"C Baldini","year":"2023","unstructured":"Baldini C., Berardicurti O., Giacomelli R., Bombardieri M. Is minor salivary gland biopsy still mandatory in Sjogren\u2019s syndrome? Does seronegative Sjogren\u2019s syndrome exist? Autoimmun. Rev. 23, 103425 (2023).","journal-title":"Autoimmun. Rev."},{"key":"1135_CR56","first-page":"3","volume":"38","author":"M Bombardieri","year":"2020","unstructured":"Bombardieri, M. et al. One year in review 2020: pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Clin. Exp. Rheumatol. 38, 3\u20139 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR57","first-page":"222","volume":"36","author":"FGM Kroese","year":"2018","unstructured":"Kroese, F. G. M., Haacke, E. A. & Bombardieri, M. The role of salivary gland histopathology in primary Sj\u00f6gren\u2019s syndrome: promises and pitfalls. Clin. Exp. Rheumatol. 36, 222\u2013233 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","volume":"18","author":"AV Goules","year":"2019","unstructured":"Goules, A. V. & Tzioufas, A. G. Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: predictive biomarkers towards precision medicine. Autoimmun. Rev. 18, 137\u2013143 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1135_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","volume":"62","author":"P Szodoray","year":"2005","unstructured":"Szodoray, P. & Jonsson, R. The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sj\u00f6gren\u2019s syndrome. Scand. J. Immunol. 62, 421\u2013428 (2005).","journal-title":"Scand. J. Immunol."},{"key":"1135_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/BOR.0000000000000473","volume":"30","author":"E Pontarini","year":"2018","unstructured":"Pontarini, E., Lucchesi, D. & Bombardieri, M. Current views on the pathogenesis of Sj\u00f6gren\u2019s syndrome. Curr. Opin. Rheumatol. 30, 215\u2013221 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1135_CR61","first-page":"222","volume":"38","author":"E Pontarini","year":"2020","unstructured":"Pontarini, E. et al. Blocking T cell co-stimulation in primary Sj\u00f6gren\u2019s syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. Clin. Exp. Rheumatol. 38, 222\u2013227 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR62","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1136\/annrheumdis-2020-217646","volume":"79","author":"E Pontarini","year":"2020","unstructured":"Pontarini, E. et al. Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sj\u00f6gren\u2019s syndrome with ectopic germinal centres and MALT lymphoma. Ann. Rheum. Dis. 79, 1588\u20131599 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/imr.12644","volume":"283","author":"ME Raeber","year":"2018","unstructured":"Raeber, M. E., Zurbuchen, Y., Impellizzieri, D. & Boyman, O. The role of cytokines in T-cell memory in health and disease. Immunol. Rev. 283, 176\u2013193 (2018).","journal-title":"Immunol. Rev."},{"key":"1135_CR64","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/art.41558","volume":"73","author":"E Rivi\u00e8re","year":"2021","unstructured":"Rivi\u00e8re, E. et al. Interleukin-7\/interferon axis drives T cell and salivary gland epithelial cell interactions in Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 73, 631\u2013640 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR65","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1136\/annrheumdis-2016-209236","volume":"75","author":"MR Hillen","year":"2016","unstructured":"Hillen, M. R. et al. High soluble IL-7 receptor expression in Sj\u00f6gren\u2019s syndrome identifies patients with increased immunopathology and dryness. Ann. Rheum. Dis. 75, 1735\u20131736 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR66","doi-asserted-by":"publisher","first-page":"243723","DOI":"10.1155\/2015\/243723","volume":"2015","author":"A Alunno","year":"2015","unstructured":"Alunno, A. et al. T regulatory and T helper 17 cells in primary Sj\u00f6gren\u2019s syndrome: facts and perspectives. Mediators Inflamm. 2015, 243723 (2015).","journal-title":"Mediators Inflamm."},{"key":"1135_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/mi.2013.61","volume":"7","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. CD8+ cells regulate the T helper-17 response in an experimental murine model of Sj\u00f6gren syndrome. Mucosal Immunol. 7, 417\u2013427 (2014).","journal-title":"Mucosal Immunol."},{"key":"1135_CR68","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1073\/pnas.1503315112","volume":"112","author":"F Barone","year":"2015","unstructured":"Barone, F. et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl Acad. Sci. USA 112, 11024\u201311029 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1135_CR69","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","volume":"13","author":"M Noack","year":"2014","unstructured":"Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun. Rev. 13, 668\u2013677 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1135_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","volume":"59","author":"ILA Bodewes","year":"2019","unstructured":"Bodewes, I. L. A., Gottenberg, J. E., van Helden-Meeuwsen, C. G., Mariette, X. & Versnel, M. A. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial. Rheumatology 59, 107\u201311 (2019).","journal-title":"Rheumatology"},{"key":"1135_CR71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"JE Gottenberg","year":"2014","unstructured":"Gottenberg, J. E. et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312, 249\u2013258 (2014).","journal-title":"JAMA"},{"key":"1135_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2478\/rir-2022-0017","volume":"3","author":"S Gandolfo","year":"2022","unstructured":"Gandolfo, S. & Ciccia, F. JAK\/STAT pathway targeting in primary Sj\u00f6gren syndrome. Rheumatol. Immunol. Res. 3, 95\u2013102 (2022).","journal-title":"Rheumatol. Immunol. Res."},{"key":"1135_CR73","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02049437 (2021)."},{"key":"1135_CR74","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/0961203316678675","volume":"26","author":"DJ Burge","year":"2017","unstructured":"Burge, D. J. et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Lupus 26, 825\u2013834 (2017).","journal-title":"Lupus"},{"key":"1135_CR75","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/art.41489","volume":"73","author":"J Posada","year":"2021","unstructured":"Posada, J. et al. Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial. Arthritis Rheumatol. 73, 143\u2013150 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-002979","volume":"9","author":"S Hamkour","year":"2023","unstructured":"Hamkour, S. et al. Leflunomide\/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sj\u00f6gren\u2019s syndrome that show potential to predict and monitor clinical response. RMD Open. 9, e002979 (2023).","journal-title":"RMD Open."},{"key":"1135_CR77","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden, E. H. M. et al. Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2, e260\u2013e269 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1135_CR78","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02780674 (2018)."},{"key":"1135_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03817424 (2020)."},{"key":"1135_CR80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaut.2018.02.001","volume":"91","author":"ILA Bodewes","year":"2018","unstructured":"Bodewes, I. L. A. et al. TBK1: a key regulator and potential treatment target for interferon positive Sj\u00f6gren\u2019s syndrome, systemic lupus erythematosus and systemic sclerosis. J. Autoimmun. 91, 97\u2013102 (2018).","journal-title":"J. Autoimmun."},{"key":"1135_CR81","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05383677 (2022)."},{"key":"1135_CR82","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/art.40589","volume":"70","author":"J Lee","year":"2018","unstructured":"Lee, J. et al. JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 70, 2057\u20132066 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR83","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","volume":"61","author":"E Price","year":"2022","unstructured":"Price, E. et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology 61, 4797\u20134808 (2022).","journal-title":"Rheumatology"},{"key":"1135_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05087589 (2022)."},{"key":"1135_CR85","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04496960 (2024)."},{"key":"1135_CR86","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04916756 (2021)."},{"key":"1135_CR87","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05016297 (2024)."},{"key":"1135_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05946941 (2024)."},{"key":"1135_CR89","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/24755303231201336","volume":"8","author":"P Kingston","year":"2023","unstructured":"Kingston, P., Blauvelt, A., Strober, B. & Armstrong, A. W. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J. Psoriasis Psoriatic Arthritis 8, 156\u2013165 (2023).","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"1135_CR90","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR91","first-page":"271","volume":"82","author":"JM Kahlenberg","year":"2023","unstructured":"Kahlenberg, J. M. et al. POS0112 deucravacitinib reduces interferons, b-cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 paisley study. Ann. Rheum. Dis. 82, 271\u2013271 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR92","first-page":"217","volume":"37","author":"S Grigoriadou","year":"2019","unstructured":"Grigoriadou, S. et al. B cell depletion with rituximab in the treatment of primary Sj\u00f6gren\u2019s syndrome: what have we learnt? Clin. Exp. Rheumatol. 37, 217\u2013224 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR93","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J. et al. Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthritis Rheum."},{"key":"1135_CR94","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec, V. et al. Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57, 310\u2013317 (2007).","journal-title":"Arthritis Rheum."},{"key":"1135_CR95","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR96","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/ard.2008.092601","volume":"68","author":"JM Meijer","year":"2009","unstructured":"Meijer, J. M., Pijpe, J., Vissink, A., Kallenberg, C. G. & Bootsma, H. Treatment of primary Sj\u00f6gren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann. Rheum. Dis. 68, 284\u2013285 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR97","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960\u2013968 (2010).","journal-title":"Arthritis Rheum."},{"key":"1135_CR98","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","volume":"71","author":"PM Meiners","year":"2012","unstructured":"Meiners, P. M. et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab. Ann. Rheum. Dis. 71, 1297\u20131302 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR99","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg, J. E. et al. Efficacy of rituximab in systemic manifestations of primary Sj\u00f6gren\u2019s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 72, 1026\u20131031 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR100","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/art.37850","volume":"65","author":"EW St Clair","year":"2013","unstructured":"St Clair, E. W. et al. Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 65, 1097\u20131106 (2013).","journal-title":"Arthritis Rheum."},{"key":"1135_CR101","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar4359","volume":"15","author":"F Carubbi","year":"2013","unstructured":"Carubbi, F. et al. Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study. Arthritis Res. Ther. 15, R172 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1135_CR102","doi-asserted-by":"publisher","first-page":"233\u2013242","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V. et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233\u2013242 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1135_CR103","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman, S. J. et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 69, 1440\u20131450 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-21","volume":"15","author":"S Brown","year":"2014","unstructured":"Brown, S. et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sj\u00f6gren\u2019s Syndrome. BMC Musculoskelet. Disord. 15, 21 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1135_CR105","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/annrheumdis-2011-201189","volume":"71","author":"N Hamza","year":"2012","unstructured":"Hamza, N. et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome after B cell depletion therapy. Ann. Rheum. Dis. 71, 1881\u20131887 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR106","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723\u2013732 (2006).","journal-title":"Arthritis Rheum."},{"key":"1135_CR107","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","volume":"66","author":"F Lavie","year":"2007","unstructured":"Lavie, F. et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66, 700\u2013703 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR108","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","volume":"125","author":"T Dorner","year":"2010","unstructured":"Dorner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464\u2013475 (2010).","journal-title":"Pharmacol. Ther."},{"key":"1135_CR109","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2021-221604","volume":"81","author":"MGA Broeren","year":"2022","unstructured":"Broeren, M. G. A. et al. Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 81, 644\u2013652 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR110","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","volume":"7","author":"X Mariette","year":"2022","unstructured":"Mariette, X. et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome. JCI Insight 7, e163030 (2022).","journal-title":"JCI Insight"},{"key":"1135_CR111","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard-2023-224999","volume":"83","author":"M Pezot","year":"2024","unstructured":"Pezot, M. et al. Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab. Ann. Rheum. Dis. 83, 407\u2013408 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong, D. P. et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat. Commun. 13, 217 (2022).","journal-title":"Nat. Commun."},{"key":"1135_CR113","first-page":"1629","volume":"390","author":"JF Howard Jr.","year":"2024","unstructured":"Howard, J. F. Jr., Vu, T. & Mozaffar, T. CAR T-cell therapy in autoimmune disease. N. Engl. J. Med. 390, 1629\u20131631 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1135_CR114","doi-asserted-by":"publisher","unstructured":"Wilhelm, A. et al. Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.179433 (2024).","DOI":"10.1172\/jci.insight.179433"},{"key":"1135_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05085431 (2021)."},{"key":"1135_CR116","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld, S. D. et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren\u2019s syndrome: an open-label phase I\/II study. Arthritis Res. Ther. 8, R129 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"1135_CR117","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.40425","volume":"70","author":"JE Gottenberg","year":"2018","unstructured":"Gottenberg, J. E. et al. Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sj\u00f6gren\u2019s syndrome: post hoc analyses from the EMBODY trials. Arthritis Rheumatol. 70, 763\u2013773 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR118","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse, M. E. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 69, 362\u2013375 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR119","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02962895 (2022)."},{"key":"1135_CR120","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05350072 (2024)."},{"key":"1135_CR121","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05349214 (2024)."},{"key":"1135_CR122","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02614716 (2018)."},{"key":"1135_CR123","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2023","unstructured":"Xu, D. et al. Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology 63, 698\u2013705 (2023).","journal-title":"Rheumatology"},{"key":"1135_CR124","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05673993 (2023)."},{"key":"1135_CR125","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms25010010","volume":"25","author":"A Tkachenko","year":"2024","unstructured":"Tkachenko, A., Kupcova, K. & Havranek, O. B-cell receptor signaling and beyond: the role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in normal and malignant B cells. Int. J. Mol. Sci. 25, 10 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04186871 (2024)."},{"key":"1135_CR127","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T Dorner","year":"2024","unstructured":"Dorner, T. et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann. Rheum. Dis. 83, 360\u2013371 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04700280 (2023)."},{"key":"1135_CR129","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","volume":"60","author":"M Juarez","year":"2021","unstructured":"Juarez, M. et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 60, 1364\u20131375 (2021).","journal-title":"Rheumatology"},{"key":"1135_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02775916 (2021)."},{"key":"1135_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03627065 (2021)."},{"key":"1135_CR132","doi-asserted-by":"publisher","first-page":"107904","DOI":"10.1016\/j.intimp.2021.107904","volume":"98","author":"MD Scuron","year":"2021","unstructured":"Scuron, M. D., Fay, B. L., Connell, A. J., Oliver, J. & Smith, P. A. The PI3K\u03b4 inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome. Int. Immunopharmacol. 98, 107904 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1135_CR133","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04968912 (2024)."},{"key":"1135_CR134","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","volume":"14","author":"V Bhandari","year":"2023","unstructured":"Bhandari, V. & Bril, V. FcRN receptor antagonists in the management of myasthenia gravis. Front. Neurol. 14, 1229112 (2023).","journal-title":"Front. Neurol."},{"key":"1135_CR135","first-page":"892","volume":"82","author":"J Hubbard","year":"2023","unstructured":"Hubbard, J. et al. POS1130 designing of a phase 2, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy and safety of nipocalimab, an FCRN inhibitor, in adults with primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 82, 892\u2013893 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05817669 (2024)."},{"key":"1135_CR137","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","volume":"80","author":"AN Baer","year":"2021","unstructured":"Baer, A. N. et al. Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann. Rheum. Dis. 80, 339\u2013348 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR138","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","volume":"2","author":"JF van Nimwegen","year":"2020","unstructured":"van Nimwegen, J. F. et al. Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2, e153\u2013e163 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1135_CR139","doi-asserted-by":"publisher","first-page":"151955","DOI":"10.1016\/j.semarthrit.2022.151955","volume":"53","author":"L de Wolff","year":"2022","unstructured":"de Wolff, L. et al. Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: the open-label extension phase of the ASAP-III trial. Semin. Arthritis Rheum. 53, 151955 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1135_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02843659 (2018)."},{"key":"1135_CR141","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3892\/mmr.2022.12864","volume":"26","author":"P Li","year":"2022","unstructured":"Li, P., Jin, Y., Zhao, R., Xue, Z. & Ji, J. Expression of ICOS in the salivary glands of patients with primary Sjogren\u2019s syndrome and its molecular mechanism. Mol. Med Rep. 26, 348 (2022).","journal-title":"Mol. Med Rep."},{"key":"1135_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00344448 (2015)."},{"key":"1135_CR143","unstructured":"U.S. Food and Drug Administration. Efalizumab (marketed as raptiva) information. FDA https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/efalizumab-marketed-raptiva-information (2019)."},{"key":"1135_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05217472 (2022)."},{"key":"1135_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02291029 (2021)."},{"key":"1135_CR146","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03905525 (2023)."},{"key":"1135_CR147","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04541589 (2024)."},{"key":"1135_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04129164 (2024)."},{"key":"1135_CR149","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2018-213340","volume":"78","author":"B Fisher","year":"2019","unstructured":"Fisher, B. et al. FRI0174 subcutaneous dosing of the novel antI-CD40 antibody iscalimab achieves target drug exposure and clinical efficacy in primary Sj\u00f6gren\u2019s syndrome; results of a phasE IIA randomised open label two arm parallel group triaL. Ann. Rheum. Dis. 78, 760\u2013761 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR150","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","volume":"185","author":"L Robles-Carrillo","year":"2010","unstructured":"Robles-Carrillo, L. et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185, 1577\u20131583 (2010).","journal-title":"J. Immunol."},{"key":"1135_CR151","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"EW St","year":"2023","unstructured":"St, E. W. et al. OP0143 efficacy and safety of DAZODALIBEP (VIB4920\/HZN4920) in subjects with Sj\u00f6gren\u2019s syndrome: a phase 2, randomized, double-blind, placebo-controlled, proof of concept sTUDY. Ann. Rheum. Dis. 82, 95\u201395 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR152","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06245408 (2024)."},{"key":"1135_CR153","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06104124 (2024)."},{"key":"1135_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04684654 (2023)."},{"key":"1135_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04572841 (2024)."},{"key":"1135_CR156","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He, J. et al. Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw. Open. 5, e2241451 (2022).","journal-title":"JAMA Netw. Open."},{"key":"1135_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04093531 (2022)."},{"key":"1135_CR158","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.4049\/jimmunol.182.3.1509","volume":"182","author":"AC Vendel","year":"2009","unstructured":"Vendel, A. C. et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J. Immunol. 182, 1509\u20131517 (2009).","journal-title":"J. Immunol."},{"key":"1135_CR159","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","volume":"110","author":"CP Mavragani","year":"2020","unstructured":"Mavragani, C. P. & Moutsopoulos, H. M. Sj\u00f6gren\u2019s syndrome: old and new therapeutic targets. J. Autoimmun. 110, 102364 (2020).","journal-title":"J. Autoimmun."},{"key":"1135_CR160","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40259-021-00505-7","volume":"35","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Targeted therapy for primary Sj\u00f6gren\u2019s syndrome: where are we now? BioDrugs 35, 593\u2013610 (2021).","journal-title":"BioDrugs"},{"key":"1135_CR161","doi-asserted-by":"publisher","first-page":"14394","DOI":"10.3390\/ijms232214394","volume":"23","author":"PH Tan","year":"2022","unstructured":"Tan, P. H., Ji, J., Hsing, C. H., Tan, R. & Ji, R. R. Emerging roles of type-I interferons in neuroinflammation, neurological diseases, and long-haul COVID. Int. J. Mol. Sci. 23, 14394 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR162","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.3390\/ijms19123953","volume":"19","author":"FR de Oliveira","year":"2018","unstructured":"de Oliveira, F. R. et al. Neurological and inflammatory manifestations in Sj\u00f6gren\u2019s syndrome: the role of the kynurenine metabolic pathway. Int. J. Mol. Sci. 19, 3953 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1135_CR163","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39629","volume":"68","author":"NI Maria","year":"2016","unstructured":"Maria, N. I. et al. Association of increased Treg cell levels with elevated indoleamine 2,3-dioxygenase activity and an imbalanced kynurenine pathway in interferon-positive primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 68, 1688\u20131699 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR164","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","volume":"1","author":"JR Tarn","year":"2019","unstructured":"Tarn, J. R. et al. Symptom-based stratification of patients with primary Sjogren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 1, e85\u2013e94 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1135_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23472-7","volume":"12","author":"P Soret","year":"2021","unstructured":"Soret, P. et al. A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome. Nat. Commun. 12, 3523 (2021).","journal-title":"Nat. Commun."},{"key":"1135_CR166","doi-asserted-by":"publisher","unstructured":"Warner, B. et al. GZMK+CD8+ T cells target a specific acinar cell type in Sjogren\u2019s disease. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-3601404\/v1 (2023).","DOI":"10.21203\/rs.3.rs-3601404\/v1"},{"key":"1135_CR167","doi-asserted-by":"publisher","first-page":"854183","DOI":"10.3389\/fimmu.2022.854183","volume":"13","author":"I Sarkar","year":"2022","unstructured":"Sarkar, I. et al. Aberrant signaling of immune cells in Sj\u00f6gren\u2019s syndrome patient subgroups upon interferon stimulation. Front. Immunol. 13, 854183 (2022).","journal-title":"Front. Immunol."},{"key":"1135_CR168","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/eji.201948129","volume":"50","author":"M van der Kroef","year":"2020","unstructured":"van der Kroef, M. et al. Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sj\u00f6grens syndrome. Eur. J. Immunol. 50, 119\u2013129 (2020).","journal-title":"Eur. J. Immunol."},{"key":"1135_CR169","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/art.42723","volume":"76","author":"MS van Ginkel","year":"2024","unstructured":"van Ginkel, M. S. et al. Increased diagnostic accuracy of the labial gland biopsy in primary Sj\u00f6gren syndrome when multiple histopathological features are included. Arthritis Rheumatol. 76, 421\u2013428 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1135_CR170","doi-asserted-by":"publisher","first-page":"1216379","DOI":"10.3389\/fimmu.2023.1216379","volume":"14","author":"D Luo","year":"2023","unstructured":"Luo, D. et al. Unraveling the transcriptome-based network of Tfh cells in primary Sjogren syndrome: insights from a systems biology approach. Front. Immunol. 14, 1216379 (2023).","journal-title":"Front. Immunol."},{"key":"1135_CR171","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","volume":"6","author":"Y Nguyen","year":"2024","unstructured":"Nguyen, Y. et al. Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. 6, e216\u2013e225 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1135_CR172","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/OARRR.S284763","volume":"14","author":"M Lorenzon","year":"2022","unstructured":"Lorenzon, M. et al. Salivary gland ultrasound in primary Sj\u00f6gren\u2019s syndrome: current and future perspectives. Open. Access. Rheumatol. 14, 147\u2013160 (2022).","journal-title":"Open. Access. Rheumatol."},{"key":"1135_CR173","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/diagnostics13172771","volume":"13","author":"G Fulvio","year":"2023","unstructured":"Fulvio, G. et al. UHFUS: a valuable tool in evaluating exocrine gland abnormalities in Sj\u00f6gren\u2019s disease. Diagnostics 13, 2771 (2023).","journal-title":"Diagnostics"},{"key":"1135_CR174","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","volume":"18","author":"R Felten","year":"2019","unstructured":"Felten, R., Scher, F., Sibilia, J., Gottenberg, J. E. & Arnaud, L. The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: a systematic review of trials. Autoimmun. Rev. 18, 576\u2013582 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1135_CR175","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1093\/rheumatology\/kead096","volume":"26","author":"R Felten","year":"2023","unstructured":"Felten, R. et al. Identification of new candidate drugs for primary Sj\u00f6gren\u2019s syndrome using a drug repurposing transcriptomic approach. Rheumatology 26, 3715\u20133723 (2023).","journal-title":"Rheumatology"},{"key":"1135_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247686 (2021)."},{"key":"1135_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05113004 (2023)."},{"key":"1135_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04988087 (2023)."},{"key":"1135_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07087-5","volume":"24","author":"W Bai","year":"2023","unstructured":"Bai, W. et al. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren\u2019s syndrome patients. Trials 24, 112 (2023).","journal-title":"Trials"},{"key":"1135_CR180","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","volume":"80","author":"R Felten","year":"2020","unstructured":"Felten, R. et al. Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann. Rheum. Dis. 80, 329\u2013338 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"KB Norheim","year":"2012","unstructured":"Norheim, K. B., Harboe, E., G\u00f8ransson, L. G. & Omdal, R. Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome \u2014 a double blind, randomised clinical trial. PLoS One 7, e30123 (2012).","journal-title":"PLoS One"},{"key":"1135_CR182","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette, X. et al. Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS). Arthritis Rheum. 50, 1270\u20131276 (2004).","journal-title":"Arthritis Rheum."},{"key":"1135_CR183","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar, V. et al. Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50, 2240\u20132245 (2004).","journal-title":"Arthritis Rheum."},{"key":"1135_CR184","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","volume":"17","author":"R Seror","year":"2015","unstructured":"Seror, R. et al. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS study. Arthritis Res. Ther. 17, 241 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1135_CR185","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","volume":"54","author":"E Pontarini","year":"2015","unstructured":"Pontarini, E. et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren\u2019s syndrome. Rheumatology 54, 1429\u20131434 (2015).","journal-title":"Rheumatology"},{"key":"1135_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04563195 (2022)."},{"key":"1135_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05124925 (2024)."},{"key":"1135_CR188","first-page":"228","volume":"38","author":"T Diekhoff","year":"2020","unstructured":"Diekhoff, T. et al. Ianalumab (VAY736) in primary Sj\u00f6gren\u2019s syndrome: assessing disease activity using multi-modal ultrasound. Clin. Exp. Rheumatol. 38, 228\u2013236 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1135_CR189","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman, S. J. et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399, 161\u2013171 (2022).","journal-title":"Lancet"},{"key":"1135_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02915159 (2020)."},{"key":"1135_CR191","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1093\/rheumatology\/kead441","volume":"63","author":"L de Wolff","year":"2024","unstructured":"de Wolff, L., Arends, S., Verstappen, G. M. & Bootsma, H. Minimal added value of separate dryness assessments compared with overall dryness in ESSPRI in patients with Sj\u00f6gren\u2019s disease. Rheumatology 63, e29\u2013e31 (2024).","journal-title":"Rheumatology"},{"key":"1135_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02334306 (2019)."},{"key":"1135_CR193","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","volume":"62","author":"D Bentley","year":"2023","unstructured":"Bentley, D., Fisher, B. A., Barone, F., Kolb, F. A. & Attley, G. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 62, 3644\u20133653 (2023).","journal-title":"Rheumatology"},{"key":"1135_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03239600 (2018)."},{"key":"1135_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04605978 (2024)."},{"key":"1135_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05781451 (2024)."},{"key":"1135_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01552681 (2019)."},{"key":"1135_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04981145 (2022)."},{"key":"1135_CR199","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror, R. et al. Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum. Dis. 75, 382\u2013389 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1135_CR200","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/rheumatology\/kev114","volume":"54","author":"D Cornec","year":"2015","unstructured":"Cornec, D. et al. Development of the Sj\u00f6gren\u2019s syndrome responder index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology 54, 1699\u20131708 (2015).","journal-title":"Rheumatology"},{"key":"1135_CR201","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends, S. et al. Composite of relevant endpoints for Sjogren\u2019s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 3, e553\u2013e562 (2021).","journal-title":"Lancet Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01135-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:46:16Z","timestamp":1732369576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":201,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01135-3","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. and F.F. have participated in randomized clinical trials of deucravacitinib (for BMS), belimumab plus rituximab (for GSK), anti-CD40L therapy (for Horizon Therapeutics), anti-CD40 therapy (for Novartis) and anti-CD20 therapy (for Novartis). G.F. and G.L.R. have participated in randomized clinical trials of deucravacitinib (for BMS), anti-CD40L therapy (for Horizon Therapeutics), anti-CD40 therapy\u00a0(for Novartis)\u00a0and anti-CD20 therapy\u00a0(for Novartis). C.B. has served as adviser or consultant for Aurina, GSK, Horizon Therapeutics\/AMGEN, Johnson and Johnson and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}